Sonoma Pharmaceuticals Reports 22% Revenue Growth to $4.35 Million for Quarter Ended December 31, 2025

Sonoma Pharmaceuticals, Inc. reported its financial results for the three and nine months ended December 31, 2025, revealing a total revenue of $4.35 million for the quarter, a 22% increase from $3.56 million in the same period last year. For the nine-month period, revenue reached $13.97 million, up 33% from $10.53 million in the prior year. The company reported a net loss of $819,000 for the quarter, a slight improvement from a loss of $928,000 in the same quarter of 2024. For the nine months, the net loss was $2.59 million, compared to $2.68 million in the previous year.

The increase in revenue was driven by significant growth in the U.S. market, where sales surged by 98% to $1.22 million, primarily due to higher sales of over-the-counter products and increased activity from both new and existing distributors. Revenue from Europe also rose by 24%, while Asia saw a 38% increase. However, Latin America experienced a 38% decline, attributed to the timing of customer orders. The gross profit for the quarter improved to $1.65 million, representing a gross margin of 38%, up from 36% in the prior year.

Operationally, Sonoma Pharmaceuticals has made strides in product development and market expansion. The company has relaunched several dermatology products in the U.S. and entered into a Master Supply Agreement with WellSpring Pharmaceutical Corporation for the sale of its Microcyn technology-based products. Additionally, the company has expanded its product offerings in the wound care segment and is actively pursuing new markets, selling products in over 55 countries worldwide. The employee headcount remained stable, with no significant changes reported.

Despite the positive revenue growth, the company faces challenges, including a cash balance that decreased to $2.56 million from $5.37 million at the end of the previous fiscal period. Sonoma reported a working capital of $7.93 million, down from $8.55 million. The company indicated that it may need to seek additional capital resources through equity offerings or debt financing to sustain operations and support its growth strategy. Management expressed concerns about the potential impact of economic conditions on its ability to raise capital, which could affect its ongoing commercialization efforts.

Looking ahead, Sonoma Pharmaceuticals remains focused on expanding its product lines and market presence while managing costs. The company is optimistic about its growth trajectory, particularly in the U.S. and European markets, but acknowledges the uncertainties related to market conditions and financing. The management's outlook emphasizes the importance of continued product innovation and strategic partnerships to drive future revenue growth and improve profitability.